Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

NCT03392779 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG: ZSP1601 25 mg
DRUG: Placebo 25mg
DRUG: ZSP1601 50 mg
DRUG: Placebo 50 mg
DRUG: ZSP1601 100 mg
DRUG: Placebo 100 mg
DRUG: ZSP1601 175 mg
DRUG: Placebo 175 mg
DRUG: ZSP1601 275 mg
DRUG: Placebo 275 mg
DRUG: ZSP1601 350 mg
DRUG: Placebo 350mg
DRUG: ZSP1601 100 mg
DRUG: Placebo 100mg
DRUG: ZSP1601 50 mg
DRUG: Placebo 50 mg
DRUG: ZSP1601 100 mg
DRUG: Placebo 100 mg

Sponsor

Guangdong Zhongsheng Pharmaceutical Co., Ltd.